Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Overcoming Resistance in Breast Cancer

June 17th 2015

Improving Endocrine Treatment Decisions in ER+ Breast Cancer

June 17th 2015

Fulvestrant in HR-Positive Breast Cancer

June 17th 2015

Palbociclib in Metastatic Breast Cancer

June 17th 2015

Tumor-Infiltrating Lymphocytes in Breast Cancer

June 17th 2015

Multigene Panel Testing in Breast Cancer

June 17th 2015

Introduction: Biomarkers in Breast Cancer

June 17th 2015

Dr. Kari Wisinski on Palbociclib for Metastatic Breast Cancer

June 10th 2015

Kari Wisinski, MD, medical oncologist with University Of Wisconsin Health and the University of Wisconsin Carbone Cancer Center, discusses the use of palbociclib for patients with ER-positive and HER2-negative breast cancer.

2015 ASCO Annual Meeting Highlights

June 5th 2015

Dr. Brufsky on Anastrozole Versus Tamoxifen in DCIS

June 3rd 2015

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).

Dr. Cristofanilli on the PALOMA3 Trial for Breast Cancer

June 3rd 2015

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, discusses the PALOMA3 trial.

Neratinib Reduces HER2+ Breast Cancer Recurrences in Phase III ExteNET Study

June 2nd 2015

Treatment with neratinib immediately following adjuvant trastuzumab plus chemotherapy modestly improved invasive disease-free survival against placebo at the cost of low-grade diarrhea in almost all patients with HER2-positive early-stage breast cancer.

Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer

May 31st 2015

In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.

Hurvitz Looks Back and Ahead at Advances in Treating HER2-Positive Breast Cancer

May 26th 2015

In a recent interview with AJHO, Sara A. Hurvitz, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer and what the future might hold.

Changing the Screening Paradigm: Study Supports Follow-up Ultrasounds for Women With Dense Breasts

May 23rd 2015

To assess the impact of additional screening, Jean M. Weigert, MD, FACR, head of breast imaging for the Hospital of Central Connecticut, conducted a retrospective chart review to see how well it worked in detecting cancers in women with dense breasts during the first 4 years of implementation statewide.

Dr. Pegram on Sequencing Therapies in HER2-Positive Breast Cancer

May 21st 2015

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

Krop Takes Stock of Targeted Therapy Advances in HER2-Positive Breast Cancer

May 20th 2015

As the field evolves, it is likely that HER2-directed agents will be used to an increasing extent instead of conventional chemotherapy, further reducing toxicity.

Dr. Anne Marie McCarthy on Measuring Breast Density with Computer Algorithms

May 13th 2015

Anne Marie McCarthy, MD, research fellow, Massachusetts General Hospital, discusses using computer algorithms to measure breast density.

Perou Discusses Genomic Characterization in Breast Cancer and Understanding Basal-Like Disease

May 8th 2015

In an interview with OncLive, Charles M. Perou, MD, explains the importance of understanding and treating each subtype differently and why oncologists should be aware of the similarities between basal-like breast cancer and other non-breast cancer tumor types.

Experts Offer Insight on BRCA1/2 Testing and Prophylactic Procedures

May 4th 2015

Optimal testing strategies for breast and ovarian cancer associated with mutations in the BRCA1/2 genes, including when to start testing and which prophylactic approach to pursue, have remained a topic of debate.